Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Nursing July 2011 Susan Simmons	Recognizing and Managing Rheumatoid Arthritis Here's what rheumatoid arthritis is, how it's diagnosed and treated, and what you can do to help patients manage the disease.
American Family Physician September 15, 2005 Rindfleisch & Muller	Diagnosis and Management of Rheumatoid Arthritis Rheumatoid arthritis is the most common inflammatory arthritis, affecting 0.8 percent of the adult population worldwide. It is a lifelong disease, although patients can go into remission. Physicians must be aware of common comorbidities.
AskMen.com June 8, 2003 Mike Davison	Dealing With Arthritis There are over 100 different types of arthritis (lumped in the rheumatic disorders group), but the two most common forms are osteoarthritis or rheumatoid arthritis.
Nurse Practitioner June 2011 Eva Hardy	Gout Diagnosis and Management: What NPs Need to Know Because primary care providers diagnose and treat the vast majority of patients with gout, it is important that they understand current guidelines and evidence-based practice.
Nurse Practitioner February 2011 Jennifer M. Belavic	Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available.
American Family Physician July 15, 2006 Junnila & Cartwright	Chronic Musculoskeletal Pain in Children: Part II. Rheumatic Causes Primary care physicians should have a working knowledge of rheumatic diseases of childhood that manifest primarily as musculoskeletal pain. Children with juvenile rheumatoid arthritis can present with painless joint inflammation and may have normal results on rheumatologic tests.
Managed Care September 2004 MargaretAnn Cross	Employers Take Stock of Illness on the Clock Presenteeism -- the condition of being on the job, but giving less than 100 percent -- is fertile ground for health plans with a suitable product.
HBS Working Knowledge November 29, 2004 Paul Hemp	If You're Sick---Stay Home! Sick employees who drag themselves to work every day cost their employers more in lost productivity than in what they contribute. Here are some ideas on how employers can cut "presenteeism."
American Family Physician July 1, 2006 Junnila & Cartwright	Chronic Musculoskeletal Pain in Children: Part I. Initial Evaluation Musculoskeletal pain can be difficult for children to characterize. A logical and consistent approach to diagnosis is recommended, with judicious use of laboratory and radiologic testing.
American Journal of Nursing February 2012	Original Research: Nurses' Presenteeism and Its Effects on Self-Reported Quality of Care and Costs This study sought to investigate the extent to which musculoskeletal pain or depression (or both) in RNs affects their work productivity and self-reported quality of care and considered the associated costs.
Pharmaceutical Executive November 1, 2012 Lauri Mitchell	Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment.
Chemistry World June 13, 2007 James Mitchell Crow	Renewed Therapeutic Promise for Arthritis Patients Three new treatments for rheumatoid arthritis, the most common chronic inflammatory joint disease in the industrialized world, offer hope to patients where existing drugs have failed.
Pharmaceutical Executive February 1, 2012 Ben Comer	Best to Market Pharm Exec's Brand of the Year: Abbott's Humira
Nurse Practitioner May 2009 Yvonne D'Arcy	Is Low Back Pain Getting on Your Nerves? The pain and disability of low back pain are the most common reasons patients seek healthcare. Here are tools for diagnosis and treatment options.
American Family Physician June 15, 2004 Kataria, & Brent	Spondyloarthropathies Identification, features and strength of recommendations of this diverse group of inflammatory arthritides.
American Family Physician September 15, 2003 Richie & Francis	Diagnostic Approach to Polyarticular Joint Pain Polyarticular joint pain (i.e., pain in more than four joints) poses a diagnostic challenge because of the extensive differential diagnosis. Consequently, family physicians need to keep the diagnosis open in evaluating patients who present with pain in multiple joints.
Nursing October 2009 Yvonne D'Arcy	Overturning barriers to pain relief in older adults This article will describe how to lower the barriers to effective pain control in older patients and provide practical tips for helping them receive the full benefit from pharmacologic and nonpharmacologic therapies.
HBS Working Knowledge July 16, 2008 Porter et al.	What Should Employers do About Health Care? Companies that cut health care costs without improving the overall value of care eventually pay a price in terms of employee absenteeism and chronic ailments.
American Family Physician September 15, 2005	Rheumatoid Arthritis: What You Should Know A patient hand out on the condition, its diagnosis and treatment options.
Pharmaceutical Executive October 1, 2006	Sales and Marketing: Where the Buck Stops Pharma's ultimate customer is the employer - the guy who pays the health plan's bill. Here's what he wants to know about drugs.
American Family Physician September 15, 2002 Patel & Lundy	Ocular Manifestations of Autoimmune Disease Because a number of these diseases may initially present with ocular symptoms, physicians should maintain a high index of suspicion to make a timely diagnosis. A thorough ophthalmic examination should be completed.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
Managed Care January 2007	The Use of Therapeutic Interchange For Biologic Therapies The stated goal of therapeutic interchange is to achieve an improved or neutral outcome with the new agent while reducing overall treatment costs.
BusinessWeek February 4, 2010	How Disease Management Works Providers have convinced many big employers that their services save money and improve employee health.
Managed Care October 2003 Martin Sipkoff	Pain Management: Health Plans Need to Take Control Insurers have not focused much on chronic pain. They should. It presents a humanitarian and business opportunity.
American Family Physician July 1, 2003 Siva et al.	Diagnosing Acute Monoarthritis in Adults: A Practical Approach Acute monoarthritis can be the initial manifestation of many joint disorders. Because patients with acute monoarthritis often present to their family physician, a proper diagnostic approach is important.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
Chemistry World February 4, 2009 Matt Wilkinson	GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Rheumatoid Arthritis: JAKing Down Inflammation In the race to market the first oral drug to compete with high-priced injectables for rheumatoid arthritis, Pfizer's tasocitinib has the home-stretch lead over Rigel, Vertex, and Incyte.
American Family Physician October 1, 2000 Kelly W. Jones, Pharm.D. & Supen R. Patel, M.D.	A Family Physician's Guide to Monitoring Methotrexate Although the drug is usually prescribed by a subspecialist, a family physician may assume responsibility for monitoring methotrexate therapy...
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
Managed Care April 2005 MargaretAnn Cross	Don't Forget Productivity Gains When Rating Health Programs Disease management conference focuses on outcome measures that address issues such as presenteeism that concern most health care purchasers.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
Managed Care February 2006 Thomas Morrow	New Rheumatoid Arthritis Treatment Has Potential to Reduce Payer's Costs B-cells and their markers, once overlooked in the pathophysiology of rheumatoid arthritis, may hold the key for a new treatment regimen.
Managed Care March 2006	HMOs Want Evidence About Arthritis Drugs Long-term research needs to be done on the cost effectiveness of biologics in fighting rheumatoid arthritis before health plans can be convinced that coverage of the new agents will save money in the long run, a recent study suggests.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool August 26, 2009 Brian Orelli	Small Change, Big Impact? A small difference in wording could have a huge effect on sales of Bristol-Myers Squibb's Orencia.
Pharmaceutical Executive December 1, 2011 Lujing Wang	The Payoff for Payers Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
The Motley Fool March 9, 2010 Brian Orelli	The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections.
Managed Care July 2006	Specialty Anti-Inflammatories See Huge Increase in Utilization Americans spent 34% more for specialty anti-inflammatory agents used to treat rheumatoid arthritis in 2005 than any other specialty drug category.
Managed Care December 2007	Headlines on Deadline ... Health insurance for all is essential, but not enough... An Ohio House bill may require fully-insured health plans to cover treatment and diagnosis for autism... etc.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
Managed Care September 2003 Thomas Morrow	Managed Care Strategy: Create Competition In Expanding Biotech Field The biotech field is booming, and insurers are scrambling to find ways to deal with the high costs of new "biologic" treatments. One strategy is to try to create more competition among the producers of biotech drugs.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
Science News November 24, 2001 Janet Raloff	Decaf May Not Always Be Best Data from a pair of large studies reported in November at the American College of Rheumatology meeting in San Francisco now suggest that a woman's choice of morning coffee may affect her joints...
Managed Care December 2005 David S. Geldmacher	The Cost Benefit to Health Plans of Pharmacotherapy for Alzheimer's Disease As with other chronic diseases of aging, early diagnosis and pharmacologic therapy may reduce the costs for enrollees with Alzheimer's disease. This article reviews patient and caregiver outcomes associated with reduced health care costs and their implications for Managed Care Organizations.